Compare GH & ALLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GH | ALLY |
|---|---|---|
| Founded | 2011 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 12.3B |
| IPO Year | 2018 | 2011 |
| Metric | GH | ALLY |
|---|---|---|
| Price | $78.81 | $41.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 13 |
| Target Price | ★ $120.05 | $51.00 |
| AVG Volume (30 Days) | 1.7M | ★ 3.3M |
| Earning Date | 04-29-2026 | 04-17-2026 |
| Dividend Yield | N/A | ★ 2.87% |
| EPS Growth | 6.74 | ★ 31.67 |
| EPS | N/A | ★ 2.37 |
| Revenue | $982,021,000.00 | ★ $7,914,000,000.00 |
| Revenue This Year | $33.30 | $24.36 |
| Revenue Next Year | $28.19 | $6.21 |
| P/E Ratio | ★ N/A | $17.61 |
| Revenue Growth | ★ 32.88 | N/A |
| 52 Week Low | $36.36 | $29.91 |
| 52 Week High | $120.74 | $47.27 |
| Indicator | GH | ALLY |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 60.04 |
| Support Level | $54.39 | $39.81 |
| Resistance Level | $114.53 | $42.36 |
| Average True Range (ATR) | 5.45 | 0.99 |
| MACD | 0.07 | 0.45 |
| Stochastic Oscillator | 16.18 | 75.90 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.